Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma

Phase 3 Completed 500 enrolled Institute of Cancer Research, United Kingdom

RandomizedOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of chemotherapy is more effective in treating recurrent malignant glioma. PURPOSE: Randomized phase III trial to compare the effectiveness of temozolomide alone to that of procarbazine, lomustine, and vincristine in treating patients who have recurrent malignant glioma.

Timeline

Start: 2002-10
Primary completion: —
Completion: 2010-09

Publications

Results Brada M, Stenning S, Gabe R, Thompson LC, Levy D, Rampling R, Erridge S, Saran F, Gattamaneni R, Hopkins K, Beall S, Collins VP, Lee SM. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol. 2010 Oct 20;28(30):4601-8. doi: 10.1200/JCO.2009.27.1932. Epub 2010 Sep 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lomustine	Small molecule	—	Oral
Subject	Temozolomide	Small molecule	100 mg/m2	Oral
Subject	Temozolomide	Small molecule	200 mg/m2	Oral
Subject	Vincristine	Small molecule	—	Intravenous
Subject	procarbazine	Small molecule	—	Oral

Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma

Summary

Timeline

Publications

Drugs

Indications